P. Aisen
Physiology · 2000–2022
A researcher in the Science corpus: 25 papers; trusts 3 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Physiology — 303 citations into it; #2,266 of 2,276 by trust here, #41 by citations
- Psychiatry and Mental health — 219 citations into it; #1,313 of 1,338 by trust here, #14 by citations
Whom P. Aisen trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts P. Aisen overall
Papers from P. Aisen's perspective
Ordered by how strongly the researchers P. Aisen trusts endorse each paper. Same corpus, a different order for every researcher.
- Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory (Journal of Neuroscience)
- Neuropathological stageing of Alzheimer-related changes
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B (Annals of Neurology)
- Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders (Nature Reviews Neuroscience)
- Current concepts in mild cognitive impairment. (Archives of Neurology)
- Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia (Proceedings of the National Academy of Sciences of the United States of America)
- The pathological process underlying Alzheimer’s disease in individuals under thirty (Acta Neuropathologica)
- Neurovascular regulation in the normal brain and in Alzheimer's disease (Nature Reviews Neuroscience)
- Propagation of Tau Misfolding from the Outside to the Inside of a Cell* (Journal of Biological Chemistry)
- Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly (Archives of Neurology)
Their papers
- Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. (2014) — 1,548 citations
- A phase 3 trial of semagacestat for treatment of Alzheimer's disease. (2013) — 1,067 citations
- Cerebrospinal Fluid Biomarker Signature in Alzheimer’s Disease Neuroimaging Initiative Subjects (2009) — 2,163 citations
- The A4 Study: Stopping AD before Symptoms Begin? (2014) — 747 citations
- Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease (2022) — 1,144 citations
- Lecanemab in Early Alzheimer's Disease. (2022) — 3,696 citations
- The Amyloid-β Pathway in Alzheimer’s Disease (2021) — 1,619 citations
- Four distinct trajectories of tau deposition identified in Alzheimer’s disease (2021) — 636 citations
- Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease (2017) — 611 citations
- Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria (2016) — 1,741 citations
- Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis (2016) — 1,062 citations
- The Preclinical Alzheimer Cognitive Composite (2014) — 799 citations
- Amyloid Deposition, Hypometabolism, and Longitudinal Cognitive Decline (2012) — 702 citations
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease (2012) — 3,500 citations
- Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) — 6,812 citations
- The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception (2011) — 1,111 citations
- The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plans (2010) — 612 citations
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (2010) — 1,591 citations
- Comparing predictors of conversion and decline in mild cognitive impairment (2010) — 615 citations
- Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease (2010) — 784 citations